AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

166.350

-3.150-1.86%

Volume:276.38K

Turnover:46.15M

Market Cap:79.67B

PE:-22.25

High:169.360

Open:167.000

Low:165.790

Close:169.500

52wk High:216.748

52wk Low:88.836

Shares:478.91M

Float Shares:478.91M

Volume Ratio:0.59

T/O Rate:0.06%

Dividend:4.08

Dividend Rate:2.45%

EPS(TTM):-7.478

EPS(LYR):-7.478

ROE:-15.83%

ROA:7.26%

PB:3.85

PE(LYR):-22.25

Loading ...

Overview Company News Filings

Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?

Simply Wall St.

Asia Morning Call-Global Markets

ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally

MT Newswires Live

Australia's CSL Rises on Launching Trials for Patented Manufacturing Process

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

MT Newswires Live

Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement

Horizon 2 Technology Enables Greater Immunoglobulin Production

THOMSON REUTERS

To Launch Clinical Trials for Horizon 2 Immunoglobulin Process

THOMSON REUTERS

CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing

THOMSON REUTERS

To Seek FDA and Ema Approval for Horizon 2

THOMSON REUTERS

CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process

THOMSON REUTERS

To Commence Horizon 2 Clinical Activities in Mid-2027

THOMSON REUTERS

ASX Dividend Stocks For Steady Income in Uncertain Markets

Simply Wall St.

CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

MT Newswires Live

Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period

THOMSON REUTERS

CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)

THOMSON REUTERS

To Submit Filings for Expanded Pediatric Indication for Andembry in First Half of Fiscal Year

THOMSON REUTERS

CSL Stock And 2 More Australian Income Shares For Steady Dividends

Simply Wall St.

CSL Stock And 2 Australian Dividend Shares For Reliable Income

Simply Wall St.

3 Australian Dividend Stocks Offering Yield When Reliable Income Is Hard To Find

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/CSL.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":166.35,"timestamp":1789094696141,"preClose":169.5,"halted":0,"volume":276365,"delay":0,"changeRate":-0.01858407079646021,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.477873879716651,"marketStatus":"Trading","change":-3.15,"latestTime":"09-11 12:44:59 AEST","open":167,"high":169.36,"low":165.79,"amount":46154483,"amplitude":0.021062,"askPrice":166.37,"askSize":78,"bidPrice":166.35,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-7.477873879716651,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789106400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":169.5,"dividendRate":0.024495,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.594008,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":169.5,"auctionPrice":167,"auctionVolume":15835,"auctionTime":1789084752163,"referenceTime":1789036203090,"auction":1,"marketStatus":"盘前竞价","timestamp":1789084752163}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.477874,"volumeRatio":0.594032,"shares":478911979,"dividePrice":4.081382,"high":169.36,"amplitude":0.021062,"preClose":169.5,"low":165.79,"week52Low":88.836,"pbRate":"3.85","psRate":"3.61","week52High":216.748,"institutionHeld":0,"latestPrice":166.35,"committee":-0.787234,"eps":-7.477873879716651,"divideRate":0.024535,"volume":276376,"delay":0,"ttmEps":-7.477873879716651,"open":167,"prevYearClose":168.21,"prevWeekClose":172.243,"prevMonthClose":169.351,"prevQuarterClose":113.256,"fiveDayClose":172.243,"twentyDayClose":134.734,"sixtyDayClose":114.815,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655296468","title":"Does CSL (ASX:CSL)'s Pediatric ANDEMBRY Win Reveal a Deeper Rare-Disease Strategy Shift?","url":"https://stock-news.laohu8.com/highlight/detail?id=2655296468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655296468?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:27","pubTimestamp":1785382062,"startTime":"0","endTime":"0","summary":"CSL recently reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 with hereditary angioedema, showing a safety profile in line with earlier studies and that most participants remained attack-free over 12 months.\nThe company now plans regulatory filings to extend ANDEMBRY’s indication to younger children, potentially widening treatment options in a part of the HAE population where approved long-term prophylactic choices remain limited.\nWe’ll now...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsls-pediatric-andembry-win-reveal-a-deeper-rare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","SG9999004303.SGD","BK4086","BK7067","LU0728928796.USD","LU1169589451.USD","CSL","BK7501","BK7511","BK7508","SGXZ23171101.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655818139","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2655818139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655818139?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:32","pubTimestamp":1785349969,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsJuly 30 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**9,038.6090.80NZX 50**13,976.67114.74DJIA51,932.67-814.65NIKKEI**61,434.19-930.73Nasdaq24,779.13","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V1ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0898667661.SGD","LU0456854461.SGD","LU0266512127.USD","LU0572939691.SGD","LU0955648018.USD","LU0011963245.USD","RIO.AU","BK5111","LU0572940350.SGD","LU0345780950.USD","LU0955669360.SGD","LU2095319765.USD","LU0320765059.SGD","BK7501","LU0390134368.USD","LU0971552673.USD","MSCI","BK4585","LU1130305938.SGD","LU1267930730.SGD","LU1023059493.AUD","LU2265009873.SGD","SG9999001143.SGD","LU0612318971.USD","LU0289960550.SGD","BK7095","LU0345781412.USD","LU0266512473.USD","CSL.AU","LU0171293334.USD","RIO.UK","IE00B3M56506.USD","BK7507","IE0034235071.USD","LU0708995401.HKD","LU0161305163.EUR","FDIQ","LU1064927863.SGD","LU0264606111.USD","BK4112","LU1481600234.SGD","LU0345777147.USD","LU0345777659.USD","LU0654597011.USD","LU2210149790.SGD","LU1804176565.USD","LU1309081286.SGD","SG9999002521.SGD","LU0831103253.SGD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655830439","title":"ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2655830439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655830439?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:58","pubTimestamp":1785293913,"startTime":"0","endTime":"0","summary":"Healthcare stocks jumped nearly 4%, leading a broad-based rally at midday Wednesday.CSL  gained almost 7% in recent trade following news that it will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process.Meanwhile, the financial sector edged up nearly 1%.Commonwealth Bank  shares inched up in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","LU0029874061.USD","BK4588","CBA.AU","XLV","BK4581","BK7501","CSL.AU","BK7135","XBI","BK4585","BK4137","BK7508","DBB","HCSG","LU0128526141.USD","BK7067","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783450","title":"Australia's CSL Rises on Launching Trials for Patented Manufacturing Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783450","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783450?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:54","pubTimestamp":1785286492,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL rises on launching trials for patented manufacturing process** Shares of biotechnology major CSLCSL.AXrise 5.6% to A$126.59, their highest since July 9** Stock on track for best d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V02K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","BK7511","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655083457","title":"CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655083457","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655083457?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:53","pubTimestamp":1785286428,"startTime":"0","endTime":"0","summary":"CSL  will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process, according to a Wednesday Australian bourse filing.The company said it expects clinical activities to start in mid-2027.The process enables greater production of immunoglobulin from the same base amount of plasma, per the filing.The company said it will obtain clinical evidence to support and finalize regulatory approval processes for Horizon 2 after its engagements with the US Food and Drug Administration and European Medicines Agency.CSL's shares rose nearly 6% in recent trading on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","LU0728928796.USD","BK7508","CSL","BK7511","LU1169589451.USD","BK7501","SGXZ23171101.USD","LU1169590202.USD","BK4086","SG9999004303.SGD","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137947072","title":"Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1137947072","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137947072?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:14","pubTimestamp":1785284061,"startTime":"0","endTime":"0","summary":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655883986","title":"Horizon 2 Technology Enables Greater Immunoglobulin Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2655883986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655883986?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7511","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878839","title":"To Launch Clinical Trials for Horizon 2 Immunoglobulin Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878839?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7508","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839865","title":"CSL Ltd - to Launch Clinical Trials to Evaluate Enhanced Plasma Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839865?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839820","title":"To Seek FDA and Ema Approval for Horizon 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839820?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7511","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655398668","title":"CSL Ltd - Will Undertake Clinical Trial Work to Confirm Efficacy and Safety of Immunoglobulin Manufactured Using Its Next Generation Horizon 2 Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2655398668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655398668?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655383987","title":"To Commence Horizon 2 Clinical Activities in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655383987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655383987?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:21","pubTimestamp":1785280912,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U1CX:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7508","BK7511","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654885173","title":"ASX Dividend Stocks For Steady Income in Uncertain Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2654885173","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654885173?lang=en_us&edition=fundamental","pubTime":"2026-07-28 21:24","pubTimestamp":1785245055,"startTime":"0","endTime":"0","summary":"With inflation signals mixed, central banks cautious and bond yields reacting to every new headline, many investors are looking for steadier income from their portfolios. That is where the Dividend Powerhouses screener comes in. It focuses on companies offering more than a 5% dividend yield that is covered, growing and stable, which can help you keep cash flow coming even as markets adjust to changing energy costs, policy risks and shifting trade patterns. In this article you will see three...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-for-steady-income-in-uncertain-markets","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CEF","PICK","BK7511","QBE.AU","BK7506","BK7508","DECU","BK7501","UYM","BEGS","GOAU","XME","CSL.AU","BK7104","BK4585","GLTR","BK7034","EVN.AU","BK4535","BK4588","VIG","VOTE","GBUG","BK7067","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654022877","title":"CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry","url":"https://stock-news.laohu8.com/highlight/detail?id=2654022877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654022877?lang=en_us&edition=fundamental","pubTime":"2026-07-28 09:52","pubTimestamp":1785203526,"startTime":"0","endTime":"0","summary":"CSL's  Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","BK4086","LU1169589451.USD","LU0728928796.USD","CSL","BK7501","BK7508","CSL.AU","SGXZ23171101.USD","BK7511","BK7067","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654671048","title":"Andembry Showed Favorable Safety; Majority Remained Attack-Free During 12-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2654671048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654671048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7508","BK7067","BK7501","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654304862","title":"CSL Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing for Andembry® (Garadacimab-Gxii) in Children with Hereditary Angioedema (Hae)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654304862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654304862?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048640","title":"To Submit Filings for Expanded Pediatric Indication for Andembry in First Half of Fiscal Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048640?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA2NHVBF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7508","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654147170","title":"CSL Stock And 2 More Australian Income Shares For Steady Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2654147170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654147170?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:20","pubTimestamp":1785147619,"startTime":"0","endTime":"0","summary":"With inflation, interest rates and energy prices all pulling at your portfolio from different directions, dependable dividend income can feel more valuable than ever. The Dividend Powerhouses (3%+ Yield) screener focuses on companies that offer more than a 5% yield, with payouts that are covered by earnings, have a record of growth and show stability through changing economic conditions. This combination can help you keep cash flowing while markets reassess growth, central bank paths and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-more-australian-income-shares-for-steady-div","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-more-australian-income-shares-for-steady-div","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QBE.AU","CSL.AU","GOLY","CSL","GDXY","VAS.AU","JDST","IAUI","DBC","GOAU","DACE.AU","OUNZ","AAAU","BTGD","BEGS","DZZ","IAU","GDXU","GLD","FGDL","GLDM","USG","DUST","DULL","GLTR","PPI","GDXJ","RING","IAUM","SGDM","JNUG","CEF","SGOL","XME","BAR","PHYS","VIG","EVN.AU","XAO.AU","UGL","GDX","GLL","GBUG","DGP","GDXD","XKO.AU","PICK","UYM","SHNY","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654563540","title":"CSL Stock And 2 Australian Dividend Shares For Reliable Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2654563540","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654563540?lang=en_us&edition=fundamental","pubTime":"2026-07-25 12:40","pubTimestamp":1784954429,"startTime":"0","endTime":"0","summary":"With inflation, energy prices and central bank policies all pulling investors in different directions, reliable income has fresh appeal. Dividend Powerhouses aim to offer just that, with stocks yielding more than 5% and dividends that are covered, growing and relatively stable. Instead of chasing the latest story, this approach focuses on companies that pay you to stay invested while you watch how inflation, growth data and policy shifts play out. In this article, three stocks from the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-for-reliable-inco","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-stock-and-2-australian-dividend-shares-for-reliable-inco","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GBUG","GLL","GOLY","EVN.AU","GDX","GDXJ","DZZ","DULL","GEAR.AU","SGOL","OZR.AU","SGDM","XAO.AU","BBOZ.AU","BAR","GLTR","GLDM","AAAU","SHNY","GDXU","NST.AU","IAUI","XJO.AU","PHYS","CSL.AU","BEGS","JDST","IAU","DBC","XME","GOAU","BTGD","UGL","CSL","DGP","VAS.AU","FGDL","XKO.AU","RING","UYM","IAUM","USG","GDXY","PPI","PICK","OUNZ","DUST","JNUG","GDXD","CEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745983","title":"3 Australian Dividend Stocks Offering Yield When Reliable Income Is Hard To Find","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745983","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653745983?lang=en_us&edition=fundamental","pubTime":"2026-07-23 17:23","pubTimestamp":1784798629,"startTime":"0","endTime":"0","summary":"With central banks weighing inflation risks, bond yields climbing, and energy costs staying elevated, dependable income has become harder to find without taking on extra stress. That is where the Dividend Powerhouses (3%+ Yield) screener comes in. It focuses on companies paying more than a 5% dividend yield that is covered by earnings, growing, and relatively stable. For investors who want cash flow that does not depend solely on price moves, this kind of discipline can be useful. In this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-offering-yield-when-reliable-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-offering-yield-when-reliable-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RING","DUST","PHYS","PMDE","BAR","CSL.AU","PPI","AAAU","XME","IAUM","CEF","DGP","DZZ","GDXY","USG","GDX","JDST","SGDM","VOTE","IAU","UGL","GLL","UYM","XJO.AU","SGOL","SHNY","GDXJ","BEGS","DECU","OUNZ","XAO.AU","FGDL","DBC","DULL","IAUI","GOLY","GOAU","SPHQ","GLDM","BTGD","GLTR","PICK","GDXU","XKO.AU","EVN.AU","GBUG","JNUG","QBE.AU","VIG","GDXD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}